SEARCH

SEARCH BY CITATION

References

  • 1
    Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 10715.
  • 2
    Maasoumy B, Wedemeyer H. Natural history of acute and chronic Hepatitis C. Best Pract Res Clin Gastroenterol 2012; 26: 40112.
  • 3
    Backus LI, Boothroyd DB, Phillips BR, et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9: e1.
  • 4
    Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52: 83344.
  • 5
    Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006; 55: 13509.
  • 6
    Hezode C, Dorival C, Zoulim F, et al. Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic non responders. First results of the french early access program (ANRS CO20-CUPIC). J Hepatol 2012; 56: S4.
  • 7
    Maasoumy B, Port K, Markova AA, et al. Eligibility, safety and efficiency of triple therapy for chronic HCV genotype 1 infection in a real world setting. Hepatology 2012; 56 (Suppl): 1030A1A.
  • 8
    EASL Clinical Practice Guidelines. management of hepatitis C virus infection. J Hepatol 2011; 55: 24564.
  • 9
    Sarrazin C, Berg T, Cornberg M, et al. Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C. Z Gastroenterol 2012; 50: 5772.
  • 10
    Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 143344.
  • 11
    Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 95865.
  • 12
    Poordad F, McCone JJ, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195206.
  • 13
    Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 120717.
  • 14
    Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 240516.
  • 15
    Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 241728.
  • 16
    Poordad F, Bronowicki JP, Gordon SC, et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012; 143: e5.
  • 17
    Estrabaud E, Vidaud M, Marcellin P, Asselah T. Genomics and HCV infection: progression of fibrosis and treatment response. J Hepatol 2012; 57: 111025.
  • 18
    Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int 2012; 32(Suppl. 1): 88102.
  • 19
    Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 21624.
  • 20
    Dusheiko G, Wedemeyer H. New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye. Gut 2012; 61: 164752.
  • 21
    Deuffic-Burban S, Deltenre P, Buti M, et al. Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology 2012; 143: 97485.
  • 22
    Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 135864.
  • 23
    Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 82532.
  • 24
    Castera L. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat 2009; 16: 30014.
  • 25
    Castera L. Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease. Best Pract Res Clin Gastroenterol 2011; 25: 291303.
  • 26
    Camma C, Petta S, Enea M, et al. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2012; 56: 85060.
  • 27
    Foster GR, Hezode C, Bronowicki JP, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011; 141: 8819 e1.
  • 28
    Gottwein JM, Scheel TK, Jensen TB, Ghanem L, Bukh J. Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. Gastroenterology 2011; 141: 106779.
  • 29
    Silva M, Kasserra C, Gupta S, et al. Antiviral Activity of Boceprevir Monotherapy in Treatment-Naive Subjects With Chronic Hepatitis C Genotype 2/3. The 21st Conference of the Asian Pacific Association for the Study of the Liver. 2011
  • 30
    Food and Drug Administration. Victrelis label information. 2011.
  • 31
    European Medicines Agency. Victrelis label information. 2012.
  • 32
    Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 70516.
  • 33
    Foster GR, Zeuzem S, Andreone P, et al. Subanalyses of the telaprevir lead-in arm in the realize study: response at week 4 is not a substitute for prior null response categorization. J Hepatol 2011; 54: S34.
  • 34
    European Medicines Agency. CHMP assessment report: Victrelis. 2011.
  • 35
    Jeffry F, Jadhav Pravin R, Shashi A, et al. Boceprevir dosing for late responders and null responders: the role of bridging data between treatment-naive and experienced subjects. Hepatology 2012. doi: 10.1002/hep.25843
  • 36
    Lawitz E, Poordad F, Bronowicki JP, et al. The effect of using lower limit of quantitation (LLQ) vs lower limit of detection (LLD) for the definition of undetectable HCV RNA: data from the RESPOND-2 and SPINT-2 trials. Hepatology 2011; 54(Suppl.): 442A.
  • 37
    Fevery B, Susser S, Lenz O, et al. Comparison of two quantitative HCV RNA assays in samples from patients treated with a protease inhibitor-based therapy: implications for response guided therapy. J Hepatol 2012; 56: S26.
  • 38
    Bronowicki JP, Davis M, Flamm S, et al. Sustained virologic response (SVR) in prior peginterferon/ribavirin (PR) treatment failures after retreatment with boceprevir (BOC)+ PR: PROVIDE Study Interim Results. J Hepatol 2012; 56: S6.
  • 39
    Jacobson IM, Marcellin P, Zeuzem S, et al. Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin. Hepatology 2012; 56: 56775.
  • 40
    Incivo. EMA label information. 2011
  • 41
    Incivec. FDA label information. 2011
  • 42
    McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 58093.
  • 43
    Bieche I, Narjoz C, Asselah T, et al. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics 2007; 17: 73142.
  • 44
    Hulskotte E, Gupta S, Xuan F, et al. Pharmacokinetic interaction between the hcv protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 2012; 56: 162230.
  • 45
    Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. Hepatology 2012; 55: 16208.
  • 46
    Poordad FF, Lawitz EJ, Reddy KR, et al. A randomized trial comparing ribavirin dose reduction versus erythropoietin for anemia management in previously untreated patients with chronic hepatitis c receiving boceprevir plus peginterferon/ribavirin. J Hepatol 2012; 56: S559.
  • 47
    Pearlman B, Ehleben C. Hepatitis C virus (HCV) genotype 1 (GT1) infection with low viral load (LVL) and rapid virological response (RVR) to peginterferon and ribavirin (PEG/RBV) can be treated without a protease inhibitor (PI), irrespective of IL-28B status or patient ethnicity. Hepatology 2012; 56(Suppl.): 268A.
  • 48
    Buti M, Agarwal K, Horsmans Y, et al. OPTIMIZE Trial: Non-inferiority of twice-daily telaprevir versus administration of every 8 hours in treatment-naïve, genotype 1 HCV infected patients. American Association for the Study of Liver Diseases (AASLD). Hepatology 2012; abstract final ID: LB-8.
  • 49
    Petta S, Craxi A. How to optimize current HCV therapy in G1 patients: predictors of response. Liver Int 2012; 33(Suppl.). In press.
  • 50
    Chopra A, Klein PL, Drinnan T, Lee SS. Optimizing antiviral treatment of HCV genotype 1 patients: management of side effects. Liver Int 2012(Suppl). In press.